title: The risk of melanoma and hematologic cancers in patients with psoriasis.
abstract: BACKGROUND
  The risk of melanoma and hematologic cancers in patients with psoriasis is controversial.
  
  
  OBJECTIVE
  We sought to assess the risk of melanoma and hematologic cancers in patients with psoriasis, and the association with different treatments.
  
  
  METHODS
  We used case-control and retrospective cohort designs to determine melanoma or hematologic cancer risk in patients with psoriasis. Risk with treatment type was assessed using Fisher exact test.
  
  
  RESULTS
  Patients with psoriasis had 1.53 times greater risk of developing a malignancy compared with patients without psoriasis (P < .01). There were no significant differences in malignancy risk among patients treated with topicals, phototherapy, systemics, or biologic agents. Patients with psoriasis and malignancy did not have significantly worse survival than patients without psoriasis.
  
  
  CONCLUSIONS
  It is possible that patients developed malignancy subsequent to the follow-up time included in the study.
  
  
  CONCLUSIONS
  Patients with psoriasis may experience an elevated risk of melanoma and hematologic cancers, compared with the general population. The risk is not increased by systemic or biologic psoriasis therapies.
authors.affiliation: University of Illinois at Chicago College of Medicine, Chicago, Illinois.
authors.forename: Shivani P
authors.initials: SP
authors.lastname: Reddy
authors.affiliation: Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Martires
authors.affiliation: Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California. Electronic address: jashinwu@gmail.com.
authors.forename: Jashin J
authors.initials: JJ
authors.lastname: Wu
mesh_terms: D000368:Aged; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use; D002140:California / Q000453:epidemiology; D016022:Case-Control Studies; D015897:Comorbidity; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D019337:Hematologic Neoplasms / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000453:epidemiology* / Q000209:etiology; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D011701:PUVA Therapy / Q000009:adverse effects; D016016:Proportional Hazards Models; D011565:Psoriasis / Q000188:drug therapy / Q000453:epidemiology* / Q000532:radiotherapy; D012189:Retrospective Studies; D012306:Risk; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000209:etiology; D016019:Survival Analysis; D014467:Ultraviolet Therapy / Q000009:adverse effects
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents
keywords: biologic; hematologic cancer; malignancy; melanoma; phototherapy; psoriasis; topical therapy